online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 9 of 12
Up
ECPB 2017, 78(2): 56–61
https://doi.org/10.25040/ecpb2017.02.056
Research articles

Total Amount and Carbohydrate Composition of colon surface mucus Layer during experimental Colitis in Rats

A. PRYSIAZHNIUK, A. SHOLOKH, Т. DOVBYNCHUK, G. TOLSTANOVA
Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease, characterized by colon surface mucus layer damage. UC if usually followed by the development of continuous hemorrhagic inflammation in colon, which does occur in rectum and spreads in proximal direction. The development of inflammatory processes in colon initiates after the impairment of intestine barrier integrity. As a result of neutrophil recruiting activation and the development of inflammatory processes the increase of epithelial barrier permeability for bacteria was observed. It was previously shown that alterations in mucus barrier structure is among early factors of early UC development. It was previously reported that the sulphatation level of mucus mucins in patients with UC were decreased; the mucus mucins are essential for maintaining of normal colon physiological functioning. The aim of this study was to investigate dynamic changes in total glycoprotein level and its carbohydrate composition at differents terms during UC in rats. The study was performed on male Wistar rats (160–180 g, n = 24). UC was induced by 6 % iodoacetamide (IA) injection, dissolved in 1 % methylcellulose (0.1 ml, per rectum). Control rats received 1 % methylcellulose solution (0.1 ml, per rectum). Animals were subjected to an autopsy in 0.5, 2, 6 hours and on the 3rd and 7th day of experiment. Total level of mucus glycoproteins, hexoses, hexosamines, fucose and sialic acids in colon mucus were measured. It was determined that total glycoprotein level significantly increased starting from 6 hr after IA enema (1.7-fold, р < 0,05), which remained unchanged on the 3rd (2-fold increase, р < 0,05) and 7th (1.8-fold increase, р < 0,05) days of experiment vs. control group. These changes were accompanied by the increase of hexose content on the 3rd (7.7-fold, р < 0,05) and 7th (5.5-fold, р < 0,05) days of experiment vs. control group. At the same time the fucose level was sharply decreased in 6 hr (3.3-fold, р < 0,05) and on the 3rd (4-fold, р < 0,05) and 7th (7.5-fold, р < 0,05) days of experimen vs. control group. The hexoasmine level was incresed in 0.5 (2.4-fold, р < 0,05), 2 (2.4-fold, р < 0,05), 6 hr (2.9-fold, р < 0,05) and on the 3rd (3.2-fold, р < 0,05) and 7th (3.9-fold, р < 0,05) days of experiment vs. control group. The sialic acid level was increased in 6 hr (1.4-fold, р < 0,05) and on the 3rd (1.3-fold, р < 0,05), 7th (1.7- fold, р < 0,05) days of experiment vs. control group. The increase of total glycoprotein level was accompanied by sharp decrease of fucose content and increase of sialic acids content in mucin carbohydrate composition. This indicates about secretion process activation of mucins, which have less ramified carbohydrate part. Although, despite taking into account the increase of total mucin amount and elongation of carbohydrate chains by the increase of hexose level, this mucus is less tight and might be hardly held on the epithelial cells surface due to the low state of ramifidation. Moreover, the decrease of the amount of glycoprotein side carbohydrate chains might lead to the increase of the epithelium susceptibility to microorganisms and foreign macromolecules, which, in its turn, support the inflammatory process in colon. The slowly progressing changes of total glycoprotein level and carbohydrate composition in surface colon mucus layer were observed during experimental colitis in rats. These changes were manifested through the increase in total glycoprotein, hexose, hexosamine, sialic acid levels while the fucose level was decreased. This might indicate about the impairment of surface colon mucus layer function during the chronic stage of UC.

Keywords: ulcerative colitis, glycoproteins, hexoses, fucose, sialic acids, hexosamines

Full text: PDF (Ukr) 253K

References
  1. 1. Barrett J, Lee J, Lees C, Prescott N, Anderson C, Philips А et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet. 2009;41:1330-1334.
  2. 2. Becker D, Lowe J. Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003;13:41-53. doi.org/10.1093/glycob/cwg054
  3. 3. Boltin D. Mucin function in inflammatory bowel disease, an update. Journal of Clinical Gastroenterology. 2013;47(2):106-111. doi.org/10.1097/MCG.0b013e3182688e73
  4. 4. Corfield A, Wagner S, Clamp J, Kriaris M, Hoskins L. Mucin degradation in the human colon: production of sialidase, sialate O-acetylesterase, N-acetylneuraminatelyase, arylesterase, and glycosulfatase activities by strains of fecal bacteria. Infection and Immunity. 1992;60(10):3971-3978.
  5. 5. Dharmani P, Leung P, Chadee K. Tumor necrosis factor-α and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis. PLoS. One. 2011;6(9):156-169.
  6. 6. Garrett W, Gordon J, Glimcher L. Homeostasis and inflammation in the intestine. Cell. 2010;140:859-870. doi.org/10.1016/j.cell.2010.01.023
  7. 7. Holota Y, Olefir Y, Dovbynchuk T, Tolstanova G. Carbohydrate composition of rat intestine surface mucus layer after ceftriaxone treatment. Ukr. Biochem. J. 2016;88(6):7-16.
  8. 8. Iskandar H, Dhere T, Farraye F. Ulcerative colitis: update on medical management. Current Gastroenterology Reports. 2015;17(11):44-60. doi.org/10.1007/s11894-015-0466-9
  9. 9. Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670-673. doi.org/10.1126/science.1129594
  10. 10. Kappelman M, Rifas-Shiman S, Porter C, Ollendorf D, Sandler R, Galanko J et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907-1913. doi.org/10.1053/j.gastro.2008.09.012
  11. 11. Lauc G, Essafi A, Huffman J, Hayward C, Knezevic A, Kattla J et al. Genomics meets glycomics-the first GWAS study of human N-glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet. 2010;6:e1001256.
  12. 12. Lauc G, Huffman J, Pucic M, Zgaga L, Adamczyk B, Muzinic A et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9:e1003225.
  13. 13. Lozupone C, Stombaugh J, Gordon J, Jansson J, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220-230. doi.org/10.1038/nature11550
  14. 14. McGovern D, Jones M, Taylor K, Marciante K, Yan X, Dubinsky M et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum. Mol. Genet. 2010;19:3468-3476.
  15. 15. McGuckin M, Hasnain S. There is a 'uc' in mucus, but is there mucus in UC? Gut. 2013;63(13):216-217.
  16. 16. Morita H, Kettlewell M, Jewell D, Kent P. Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects. Gut. 1993;34(7):926-32. doi.org/10.1136/gut.34.7.926
  17. 17. Shui J, Liu X, Liu J, Yang X, Lu F. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J. of Gastroenterol. 2014;20(24):9468-947.
  18. 18. Smith P, Myers J, Rogers C, Zhou L, Petryniak B, Becker D et al. Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. J. Cell Biol. 2002;158:801-815. doi.org/10.1083/jcb.200203125
  19. 19. Sun J, Shen X, Li Y, Guo Z, Zhu W, Zuo L et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease. Nutrients. 2016;8(1):E4418.
  20. 20. Tailford L, Owen C, Walshaw J, Crost E, Hardy-Goddard J, Le Gall G et al. Discovery of intramolecular trans-sialidases in human gut microbiota suggests novel mechanisms of mucosal adaptation. Nat Commun. 2015;8(6):7624. doi.org/10.1038/ncomms8624
  21. 21. Tolstanova G, Deng X, French S, Lungo W, Paunovic B, Khomenko T et al. Lab Invest. 2012;92(1):9-21.
  22. 22. Van der Post S, Subramani D, Backstrom M, Johansson M, Vester-Christensen M, Mandel U, et al. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). J. Biol. Chem. 2013;288:14636-14646.
  23. 23. Valatas V, Bamias G, Kolios G. Experimental colitis models: Insights into the pathogenesisof inflammatory bowel disease and translational tissues. European Journal of Pharmacology. 2015;759(7):253–264. doi.org/10.1016/j.ejphar.2015.03.017
  24. 24. Xavier R, Podolsky D. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. doi.org/10.1038/nature06005


Програмування - Roman.im